Bispecific binding proteins and uses thereof

Patent metadata

Field	Value
Publication number	US-10457732-B2
Application number	US-201715588271-A
Country	US
Kind code	B2
Filing date	May 5, 2017
Priority date	May 6, 2016
Publication date	Oct 29, 2019
Grant date	Oct 29, 2019

Abstract

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

First claim

What is claimed is:

1. A bispecific binding protein that binds to PD-1 and CTLA-4 comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 9, a first light chain comprising the amino acid sequence of SEQ ID NO: 7, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 12, and a second light chain comprising the amino acid sequence of SEQ ID NO: 4.

2. The protein of claim 1 comprising an Fc region, wherein the Fc region is aglycosylated.

3. The protein of claim 1 comprising an Fc region, wherein the Fc region is deglycosylated.

4. The protein of claim 1 comprising an Fc region, wherein the Fc region has reduced fucosylation or is afucosylated.

5. A composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.

6. A nucleic acid molecule comprising a nucleotide sequence encoding a protein of claim 1 .

7. A vector comprising the nucleic acid molecule of claim 6 .

8. An isolated host cell comprising the vector of claim 7 .

9. A method of treating or preventing cancer in a subject, the method comprising administering the protein of claim 1 to the subject.

10. The method of claim 9 , wherein the cancer is one or more of ovarian cancer, breast cancer, colorectal cancer, prostate cancer, cervical cancer, uterine cancer, testicular cancer, bladder cancer, head and neck cancer, melanoma, pancreatic cancer, renal cell carcinoma, and lung cancer.

11. A method of enhancing an immune response in a subject, the method comprising administering the protein of claim 1 to the subject.

12. The nucleic acid molecule of claim 6 , wherein the nucleotide encoding the protein of claim 1 comprises a nucleotide sequence encoding a first heavy chain, comprising the nucleotide sequence of SEQ ID NO: 10; a nucleotide sequence encoding a first light chain, comprising the nucleotide sequence of SEQ ID NO: 8; a nucleotide sequence encoding a second heavy chain, comprising the nucleotide sequence of SEQ ID NO: 13; and a nucleotide sequence encoding a second light chain, comprising the nucleotide sequence of SEQ ID NO: 11.

Assignees

• Medimmune Llc

Inventors

• Kasturirangan Srinath
• Gao Changshou
• Rainey Godfrey
• Morrow Michelle
• Dobson Claire Louise
• Drabic Stacey
• Schofield Darren
• Carlesso Gianluca
• Pollizzi Kristen
• Mazor Yariv
• Oberst Michael
• Hammond Scott A
• Lobo Brian
• Manikwar Prakash
• Seaman Jonathan
• Dovedi Simon
• Herbst Ronald

Classifications

• C07K2317/732

  Antibody-dependent cellular cytotoxicity [ADCC] · CPC title

• C07K2317/33

  Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity · CPC title

• C07K16/2803

  against the immunoglobulin superfamily · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K2039/505

  comprising antibodies · CPC title